JPRN-UMIN000035537
Not yet recruiting
Phase 2
A phase 2 study to evaluate safety and efficacy of laparoscopic sleeve gastrectomy with duodenojejunal bypass for obesity with diabetes mellitus - A phase 2 study of laparoscopic sleeve gastrectomy with duodenojejunal bypass
ConditionsMorbid obesity with diabetes mellitus
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Morbid obesity with diabetes mellitus
- Sponsor
- Kansai Medical University Hospital
- Enrollment
- 33
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Severe organ dysfunction
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
A phase 2 study to evaluate safety and efficacy of laparoscopic sleeve gastrectomy+duodenojejunostoy for morbid obese patients with diabetes mellitus (Advanced medical care A)Morbid obese patients with diabetes mellitusJPRN-UMIN000030837Tohoku University Hospital10
Recruiting
Not Applicable
A phase 2 study to evaluate safety and efficacy of laparoscopic sleeve gastrectomy+duodenojejunostoy for morbid obese patients with diabetes mellitusMorbid obese patients with diabetes mellitusJPRN-UMIN000016208Tohoku University Hospital10
Active, not recruiting
Phase 1
A phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failureRecurrent unresectable or metastatic cervix carcinomaMedDRA version: 21.1Level: PTClassification code 10008344Term: Cervix carcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-002184-97-FRCentre François Baclesse57
Recruiting
Phase 2
uPBSCT with PTCY for ATadult T-cell leukemia/lymphomaJPRN-jRCTs031200375Fukuda Takahiro24
Recruiting
Not Applicable
Phase II study to evaluate efficacy and safety of retherapy with bendamustine and rituximab regimens in patients with relapsed/refractory indolent B-cell lymphomas and mantle cell lymphomasJPRN-UMIN000011152B-SRIM Study Group38